{
    "root": "347ade48-52bd-9405-e063-6294a90a8d04",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250506",
    "ingredients": [
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        }
    ],
    "indications": "Pantoprazole sodium  delayed-release tablets are indicated for:",
    "contraindications": "* Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily",
    "warningsAndPrecautions": "Pantoprazole Sodium Delayed-Release Tablets USP, 40 mg are yellow colored, oval shaped, biconvex, enteric-coated tablets imprinted with ‘I’ and ‘52’ with brown ink on one side and plain on other side.\n                  NDC: 70518-1298-00\n                  NDC: 70518-1298-01\n                  NDC: 70518-1298-02\n                  NDC: 70518-1298-03\n                  NDC: 70518-1298-04\n                  NDC: 70518-1298-05\n                  NDC: 70518-1298-06\n                  NDC: 70518-1298-07\n                  NDC: 70518-1298-08\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 28 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria\n  \n   [see\n                        \n                           Warnings and Precautions (5.2),\n  \n   \n                        \n                           Adverse Reactions (6)].\n  \n   \n                     \n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products\n  \n   [see\n   \n    Drug Interactions (7)]\n  \n   ."
}